DRG Market Assessment reports

Amid Significant Unmet Need, What Magnitude of Efficacy and Safety Do Pulmonologists and Payers Expect of an Emerging Therapy? Although several effective anti-inflammatory agents and…

To view the recording from our webinar series, please select the video link to the left   Outline – Background – Overarching theme of the EGA conference – Current and future startegies to drive…

Opportunity Awaits Therapies Offering Improvements in Efficacy and Safety over Currently Available TNF-Alpha Inhibitors The availability of tumor necrosis factor alpha (TNF-α) inhibitors as…

Opportunity Awaits Therapies Offering Improvements in Efficacy and Safety over Currently Available TNF-Alpha Inhibitors The availability of tumor necrosis factor alpha (TNF-α) inhibitors as…

Significant Market Opportunity Awaits Therapies Offering Improvements in Efficacy over IV Belimumab for the Moderate to Severe Patient Segment Systemic lupus erythematosus (SLE) is a complex…

Significant Market Opportunity Awaits Therapies Offering Improvements in Efficacy over IV Belimumab for the Moderate to Severe Patient Segment Systemic lupus erythematosus (SLE) is a complex…

Are emerging targeted therapies poised to fill the significant unmet need of patients in the second and subsequent lines of therapy? Treatment decisions for non-small-cell lung cancer (NSCLC)…

Are emerging targeted therapies poised to fill the significant unmet need of patients in the second and subsequent lines of therapy? Treatment decisions for non-small-cell lung cancer (NSCLC)…

Although the postoperative pain market is sizeable in terms of both dollars and the potential patient pool, treatment is very fragmented, with many drugs and formulations available within each drug…

Gauging Physicians’ and Payers’ Evolving Receptivity to Emerging Symptomatic vs. Disease-Modifying Therapies With aging populations, the seven major pharmaceutical markets face an ever-…

Gauging Physicians’ and Payers’ Evolving Receptivity to Emerging Symptomatic vs. Disease-Modifying Therapies With aging populations, the seven major pharmaceutical markets face an ever-…

LaunchTrends: Gilotrif is a series of three post-launch syndicated reports designed to track physician perception and uptake of newly launched Gilotrif (Boehringer Ingelheim’s afatinib)…